Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | TGFBR1 | P36897 | 4/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | PTPRB | P23467 | 1/20 | 0.30 |
| ▸ | RORC | P51449 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3838833 | 0.88 | F2 (0.34) | F2ALDH1A1MAPTTGFBR1PKM | |
| SCHEMBL7190508 | 0.87 | F2 (0.42) | F2ALDH1A1MAPTTGFBR1PKM | |
| SCHEMBL3838836 | 0.82 | TGFBR1 (0.34) | ALDH1A1MAPTTGFBR1PKMSMN1; SMN2 | |
| SCHEMBL3809843 | 0.80 | POLB (0.40) | ALDH1A1MAPTPKMSMN1; SMN2LMNA | |
| SCHEMBL3811615 | 0.77 | ALDH1A1 (0.53) | ALDH1A1MAPTPKMLMNA | |
| SCHEMBL4954940 | 0.76 | MAPT (0.42) | ALDH1A1MAPTPKMSMN1; SMN2 | |
| SCHEMBL7196567 | 0.75 | F2 (0.38) | F2ALDH1A1MAPTTGFBR1SMN1; SMN2 | |
| SCHEMBL7187086 | 0.74 | F2 (0.37) | F2ALDH1A1MAPTTGFBR1PKM | |
| SCHEMBL7190513 | 0.73 | F2 (0.41) | F2ALDH1A1MAPTTGFBR1PKM | |
| SCHEMBL7197201 | 0.73 | F2 (0.36) | F2ALDH1A1MAPTTGFBR1PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1235595-B8 | INTEGRIN-MEDIATED DRUG TARGETING | BAYER SCHERING PHARMA AG (DE) | 2009-10-07 | — | — | EP | disclosed |
| EP-1235595-B1 | INTEGRIN-MEDIATED DRUG TARGETING | ALBERS MARKUS (DE) | 2009-08-05 | — | — | EP | disclosed |
| US-7220824-B1 | Integrin-mediated drug targeting | BAYER AKTIENGESELLSCHAFT (DE) | 2007-05-22 | — | — | US | disclosed |
| US-20060189544-A1 | Integrin-Mediated drug targeting | BAYER AKTIENGESELLSCHAFT (DE) | 2006-08-24 | — | — | US | disclosed |
| EP-1235595-A2 | INTEGRIN-MEDIATED DRUG TARGETING | Bayer Aktiengesellschaft (DE) | 2002-09-04 | — | — | EP | disclosed |
| WO-2001017563-A2 | INTEGRIN-MEDIATED DRUG TARGETING | BAYER AKTIENGESELLSCHAFT (DE) | 2001-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060189544-A1 | Integrin-Mediated drug targeting | ITGAV, ITGB3, ITGB1 | F2 2178/4885ALDH1A1 1836/4885MAPT 4081/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.